Ocugen Inc. (OCGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
OCGN Price/Volume Stats
| Current price | $0.46 | 52-week high | $3.11 |
| Prev. close | $0.45 | 52-week low | $0.44 |
| Day low | $0.44 | Volume | 12,251,600 |
| Day high | $0.47 | Avg. volume | 6,873,851 |
| 50-day MA | $0.76 | Dividend yield | N/A |
| 200-day MA | $1.39 | Market Cap | 104.84M |
OCGN Stock Price Chart Interactive Chart >
Ocugen Inc. (OCGN) Company Bio
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of transformative therapies to cure blindness diseases. The company's pipeline product includes OCU200, a novel fusion protein that is in preclinical development stage for the treatment of wet AMD, diabetic retinopathy, and diabetic macular edema; OCU400 to treat retinitis pigmentosa, a group of rare genetic disorders; and OCU410, which is in preclinical development stage for the treatment of dry AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. The company is headquartered in Malvern, Pennsylvania.
Latest OCGN News From Around the Web
Below are the latest news stories about OCUGEN INC that investors may wish to consider to help them evaluate OCGN as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time for a dive into the biggest pre-market stock movers as we check out all of the latest news for Wednesday morning! |
Ocugen (OCGN) Q1 2023 Earnings Call TranscriptJoining me today are Ocugen's chairman, CEO and co-founder; Dr. Shankar Musunuri, who will provide a business update; and our chief financial officer and chief business officer, Quan Vu, who will provide a financial update. Earlier this morning, we issued a press release detailing business and operational highlights for the first quarter of 2023. |
Ocugen Provides Business Update with First Quarter 2023 Financial ResultsConference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)Received Orphan Drug Designation (ODD) from the FDA for OCU410ST for the Treatment of ABCA4-Associated Retinopathies Including Stargardt, Retinitis Pigmentosa (RP19), and Cone-Rod Dystrophy 3 (CORD3) DiseasesSubmitted Multiple Proposals for Federal Funding of Ocugen’s Inha |
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial ResultsMALVERN, Pa., April 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s first quarter 2023 financial results and provide a business update at 8:30 a.m. ET on Friday, May 5, 2023. Ocugen will issue a pre-market earnings announcement on the s |
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated RetinopathiesU.S. Food & Drug Administration (FDA) grants orphan drug designation to OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt, RP19 and CORD3MALVERN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the FDA has granted Orphan Drug Designation for its OCU410ST (AAV5-hRORA) |
OCGN Price Returns
| 1-mo | -35.54% |
| 3-mo | -53.82% |
| 6-mo | -70.51% |
| 1-year | -80.75% |
| 3-year | 48.39% |
| 5-year | -99.66% |
| YTD | -64.62% |
| 2022 | -71.43% |
| 2021 | 148.63% |
| 2020 | 251.92% |
| 2019 | -90.37% |
| 2018 | -95.61% |
Loading social stream, please wait...